If you are a fan of wildlife shows, you’ve probably seen those tiny video cameras rigged to animals in the wild that provide a sneak peek into their secret domains. But not all research cams are mounted on creatures with fur, feathers, or fins. One of NIH’s 2014 Early Independence Award winners has developed a baby-friendly, head-mounted camera system (shown above) that captures the world from an infant’s perspective and explores one of our most human, but still imperfectly understood, traits: language.
Elika Bergelson Credit: Zachary T. Kern
Elika Bergelson, a young researcher at the University of Rochester in New York, wants to know exactly how and when infants acquire the ability to understand spoken words. Using innovative camera gear and other investigative tools, she hopes to refine current thinking about the natural timeline for language acquisition. Bergelson also hopes her work will pay off in a firmer theoretical foundation to help clinicians assess children with poor verbal skills or with neurodevelopmental conditions that impair information processing, such as autism spectrum disorders.
For many young scientists, nothing can equal the chance to have a lab of one’s own. Still, it often takes considerable time to get there. To help creative minds cut to the chase sooner, the NIH Director’s Early Independence Awards this year will enable 17 outstanding young researchers to skip post-doctoral training and begin running their own labs immediately.
Today, I’d like to tell you about one of these creative minds. His name is Aaron Meyer, a cell signaling expert at the Massachusetts Institute of Technology in Cambridge, and his research project will take aim at one the biggest challenges in cancer treatment: chemotherapy resistance.
Today, I’d like to share a video that tells the inspirational story of two young Massachusetts Institute of Technology (MIT) researchers who are taking aim at a genetic disease that has touched both of their lives. Called myotonic dystrophy (DM), the disease is the most common form of muscular dystrophy in adults and causes a wide variety of health problems—including muscle wasting and weakness, irregular heartbeats, and profound fatigue.
If you’d like a few more details before or after watching these scientists’ video, here’s their description of their work: “Eric Wang started his lab at MIT in 2013 through receiving an NIH Early Independence Award. Learn about the path that led him to study myotonic dystrophy, a disease that affects his family. Eric’s team of researchers includes Ona McConnell, an avid field hockey goalie who is affected by myotonic dystrophy herself. Determined to make a difference, Eric and Ona hope to inspire others in their efforts to better understand and treat this disease.”
When most people think about cancer treatments, what typically come to mind are the side effects of traditional chemotherapy: cardiac, liver, and renal toxicity; hair loss; nausea; fatigue—just to name a few. These side effects occur because the cancer drugs damage not just cancer cells, but healthy cells as well. “Targeted” cancer therapy, on the other hand, is designed to target just the cancer cells. Some targeted therapies achieve this because they only attack cells with a particular molecular signature; others are directed to the cancer by physical means. Today, I’d like to introduce you to a researcher who’s developing a targeted drug delivery strategy that uses lasers and light activated drug delivery to fight cancer.
Jonathan Lovell, a Canadian-born researcher at the State University of New York at Buffalo (UB) and recipient of the NIH Director’s Early Independence Award, has designed unique nanosized spherical pods—1/1000 the diameter of a human hair—that open when light shines on them and snap shut in the dark. Lovell will fill these pods, also known as liposomes—hollow fat droplets—with anti-cancer drugs. He’ll then inject them into the body, where they’ll circulate, safely and silently: until they’re activated. When Lovell shines a red laser on the tumor, the light triggers the balloons to open and deliver a blast of the drug—only where it is needed. (Red light penetrates human tissue better than other colors.) It’s a terrific example of how bioengineering can bring fresh solutions to longstanding medical challenges.
One of the most debilitating, and heartbreaking, consequences of Alzheimer’s disease is the way it slowly robs people of their memories. Unfortunately, we don’t yet have a cure for Alzheimer’s, let alone a good understanding of exactly how this disease destroys memory skills. That’s why, in this first post in my series highlighting some of the awardees in NIH Common Fund’s High-Risk, High-Reward Research Program, I’m excited to introduce a young scientist who’s using some cool technology to tackle this formidable challenge: Christine Ann Denny.
A winner of a 2013 NIH Director’s Early Independence Awards (often called the “skip-the-postdoc” award), Denny has developed a technique to label the cells that encode individual memories in the brains of mice. That’s right: she tags the nerve cells that build these memories, the neurons, with a fluorescent molecule that glows. Continue reading →